Vical to present results of Vaxfectin adjuvant at Conference in Hungary

NewsGuard 100/100 Score
Nov 20 2010

Vical Incorporated (Nasdaq:VICL) today announced that the company is presenting an overview of results for its patented Vaxfectin® adjuvant at the Modern Veterinary Vaccines & Adjuvants conference (Budapest, Hungary, November 17 – 19).

Vaxfectin® has demonstrated promising results in a broad range of animal studies in infectious disease and cancer vaccine applications including DNA, protein and peptide vaccines, as well as initial human studies with pandemic influenza DNA vaccines. The company is exploring international partnering opportunities for veterinary applications of its technologies to supplement its existing pipeline of independent and collaborative programs.

Source: Vical Incorporated 

Posted in: Medical Condition News | Disease/Infection News | Pharmaceutical News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

Regular late-life exercise has a beneficial impact on DNA damage and telomere dysfunction
New approach to inhibit strep’s DNA-cleaving enzymes
Placental DNA methylation patterns altered by pregnancy air pollution exposure, research reveals
Study highlights the role of dynamic DNA structures in memory consolidation
DNA repair process key to memory formation, study finds
DNA origami vaccine DoriVac paves way for personalized cancer immunotherapy
Discovery of DNA repair mechanism advances understanding of how human cells stay healthy
Study reveals e-cigarette users with limited smoking history show similar DNA alterations as smokers

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Link between aldehydes and premature aging revealed